Cargando…
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
BACKGROUND: Ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), binds to a unique conformational epitope, thereby depleting B cells very efficiently and allowing subcutaneous administration at lower doses. OBJECTIVES: Th...
Autores principales: | Yu, Huixin, Graham, Gordon, David, Olivier J., Kahn, Joseph M., Savelieva, Marina, Pigeolet, Etienne, Das Gupta, Ayan, Pingili, Ratnakar, Willi, Roman, Ramanathan, Krishnan, Kieseier, Bernd C., Häring, Dieter A., Bagger, Morten, Soelberg Sørensen, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927028/ https://www.ncbi.nlm.nih.gov/pubmed/35233753 http://dx.doi.org/10.1007/s40263-021-00895-w |
Ejemplares similares
-
Safety experience with continued exposure to ofatumumab in patients
with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022) -
Efficacy and safety of ofatumumab in recently diagnosed,
treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and
II
por: Gärtner, Jutta, et al.
Publicado: (2022) -
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022) -
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022) -
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
por: Bar-Or, Amit, et al.
Publicado: (2022)